Chemotherapy Toxicity in Older Adults Optimized by Geriatric Assessment and Intervention: A Non-Comparative Analysis

Munzir Hamid 1,*, Michelle Hannan 1, Nay Myo Oo 1, Paula Lynch 1, Darren J. Walsh 1, Tara Matthews 1, Stephen Madden 2, Miriam O’Connor 1, Paula Calvert 1 and Anne M. Horgan 1,*

1 Oncology Department, University Hospital Waterford, X91 ER8E Waterford, Ireland
2 Data Science Centre, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland
* Correspondence: munzir.hamid@hse.ie (M.H.); annem.horgan@hse.ie (A.M.H.)

Abstract: The Comprehensive Geriatric Assessment (CGA) is recommended to guide treatment choices in older patients with cancer. Patients ≥ 70 years referred to our oncology service with a new cancer diagnosis are screened using the G-8. Patients with a score of ≤ 14 are eligible to attend the Geriatric Oncology and Liaison (GOAL) Clinic in our institution, with referral based on physician discretion. Referred patients undergo multidimensional assessments at baseline. CGA domains assessed include mobility, nutritional, cognitive, and psychological status. Chemotherapy toxicity risk is estimated using the Cancer Aging and Research Group (CARG) calculator. We undertook a retrospective analysis of patients attending the GOAL clinic over a 30-month period to April 2021. The objective was to determine rates of treatment dose modifications, delays, discontinuation, and unscheduled hospitalizations as surrogates for cytotoxic therapy toxicity in these patients. These data were collected retrospectively. Ninety-four patients received chemotherapy; the median age was 76 (70–87) and 45 were female (48%). Seventy-five (80%) had an ECOG PS of 0–1. Seventy-two (77%) had gastrointestinal cancer, and most had stage III (47%) or IV (40%) disease. Chemotherapy with curative intent was received by 51% (n = 48) and 51% received monotherapy. From the CGA, the median Timed Up and Go was 11 s (7.79–31.6), and 90% reported no falls in the prior 6 months. The median BMI was 26.93 (15.43–39.25), with 70% at risk or frankly malnourished by the Mini Nutritional Assessment. Twenty-seven (29%) patients had impaired cognitive function. Forty-three (46%) had a high risk of toxicity based on the baseline CARG toxicity calculator. Twenty-six (28%) required dose reduction, 55% (n = 52) required a dose delay, and 36% (n = 34) had a hospitalization due to toxicity. Thirty-nine patients (42%) discontinued treatment due to toxicity. Despite intensive assessment, clinical optimization and personalized treatment decisions, older adults with cancer remain at high risk of chemotherapy toxicity.

Keywords: chemotherapy; toxicity; geriatric assessment; healthcare utilization

1. Introduction

Cancer is a disease of older adults, with 48% of people diagnosed over the age of 70, with this expected to rise to 58% by the year 2035 [1]. Oncologists are interested in valid and reliable tools to assess older patients undergoing cancer therapy in an effort to reduce treatment toxicities, decrease unnecessary delays, and better guide dose modifications [2–5]. Concerns regarding treatment tolerance drive the use of treatment modifications based on chronological age [6–8] rather than functional status [9,10]. Toxicity is affected not only by changes in body organ function [11], but also by other factors, such as nutritional [12], psychological factors [13,14], and polypharmacy [15].

The American Society of Clinical Oncology (ASCO), The International Society of Geriatric Oncology (SIOG), the National Cancer Control Network (NCCN), and others, recommend a Comprehensive Geriatric Assessment (CGA) for older patients with cancer [16–19]. The CGA is a multidimensional assessment of the functional status, comorbidities, mental...
health, social support, polypharmacy, and nutritional status of older adults [20,21]. Several prospective cohort studies have shown the benefit of the CGA in the assessment of older patients undergoing cancer therapy, leading to a better prediction of toxicity risk, and thus guiding treatment choices [22–25]. Data show that CGA contributes to cancer therapy decision-making in 20–50% of cases [3,16,25], with functional status, nutritional status, and comorbidities having the highest impact on decision-making [26–28]; functional impairment and older age increases the likelihood of dose modification of cytotoxic drugs [29]. Interventions driven by CGA have been shown in randomized controlled trials to increase the probability of completing scheduled chemotherapy, decreasing rates of dose reductions [30], and leading to significant reductions in serious cytotoxic treatment side-effects [31,32]. Integrating assessment with geriatrician leadership has also proven beneficial in improving health-related quality of life and decreasing both hospital admissions and treatment discontinuation in older adults receiving systemic therapy [33].

The Geriatric Oncology and Liaison (GOAL) Clinic in our centre is a service developed specifically for patients aged 70 and older with a solid cancer diagnosis, and it is the first dedicated geriatric oncology clinic at a major Irish cancer centre. New patients referred to medical oncology are screened using the G-8 screening tool [34]. Those scoring ≤ 14 are deemed suitable for the full CGA, which incorporates assessments of function, mobility, nutrition, psychosocial wellbeing, and cognition. All patients undergo a pharmacist-directed drug reconciliation and quantification of toxicity risk using validated tools. Outcomes generate multidisciplinary input by specialists in geriatric medicine, psychiatry of old age services, occupational therapy, physiotherapy, dietetic, and social work services where indicated.

We sought to determine the rates of treatment dose modifications, delays, discontinuation, and unscheduled hospitalizations as surrogates for cytotoxic therapy toxicity in patients attending the GOAL clinic. Furthermore, we aimed to determine if the CGA variables not incorporated in established prediction tools (CRASH/CARG) [35,36] could predict treatment toxicity.

2. Materials and Methods

2.1. GOAL Clinic

The GOAL clinic was developed in University Hospital Waterford, South East Cancer Centre. This is a teaching hospital, and one of the eight designated cancer centres in Ireland, serving a population of c500,000. Referral to the GOAL clinic is based on age, G-8 scores, and physician discretion. G-8 screening is undertaken by an Advanced Nurse Practitioner (ANP). This was initially restricted to patients with gastrointestinal malignancies. The GOAL clinic has evolved, and the G-8 is now completed on all patients ≥ 70 years referred to the medical oncology department prior to the first review. The G-8 results are relayed back to the assigned medical oncologist with a suggestion to refer to the GOAL clinic when G-8 ≤ 14. The ultimate decision to refer is with the treating oncologist, with a 70% referral rate noted. The CGAs completed are outlined below. These are undertaken by the ANP on the day of the first clinical consultation. The results are available to the oncology team when first assessing the patient and assist in directing treatment choice and baseline dosing. The CARG toxicity risk can aid in the dosing decision but does not dictate it—the ultimate decision relies on clinical discretion. All data are uploaded to an excel data sheet post-review. Interventions are suggested based on any deficits identified and appropriate referrals are initiated by the ANP. (See Supplementary Table S1). Fast track access to the Waterford Integrated Care for Older Patients (WICOP) has been established to facilitate rapid review of patients where indicated.

2.2. Overall Design

We undertook a retrospective analysis of data collected on all patients seen in the GOAL clinic at our institution over a 30-month period to April 2021. We only included pa-
patients who received cytotoxic treatment. Patients receiving hormonal therapy, immunotherapy, surgery, radiation therapy, or best supportive care alone were excluded.

2.3. Data Collection

Data collected were baseline demographics (age and gender), cancer type and disease stage, treatment intent (curative or palliative), and chemotherapy regimen (monotherapy or polytherapy). The CGAs included the Timed Up and Go (TUG) [37], history of falls in the last 6 months (yes or no), and number of concomitant medications. Nutrition was assessed using the mini nutritional assessment (MNA) [38,39] and scores were interpreted as malnutrition (0–7), at risk of malnutrition (8–11), and normal (12–14). Body mass index was recorded. Depression was screened for using the 15-item Geriatric Depression Scale (GDS-15) [40], with scores ≤ 5 considered normal and scores of >5 suggested depression. We collected scores of Katz Activities of Daily Living (ADL) with scores between 0–6 (0 very dependent and 6 independent) [41], Lawton Instrumental ADL, a summary score ranges from 0 (low function, dependent) to 9 (high function, independent), and Eastern Cooperative Oncology Group (ECOG) Performance Status [42]. Comorbidities were collected using the Charlson Comorbidity Index [43] and quantified as mild (1–2); moderate (3–4); and severe (≥5). Cognitive assessment was performed using the Mini-cog test [33] or 6CIT [44]. If impairments were noted, then patients proceeded to a Montreal Cognitive Assessment (MOCA) [45]. Results were divided into cognitive impairment or no impairment. The results of chemotherapy toxicity risk, estimated using the Cancer Aging and Research Group (CARG) calculator [34], were categorized into low (0–5), intermediate (6–9), and high (≥10) risk. The rates of baseline chemotherapy dose reduction were collected. This was recorded in the GOAL database. We identified subsequent dose reductions (defined as any reduction from baseline dose), dose delays, treatment discontinuations, or unscheduled hospitalizations as surrogates of treatment toxicity. The chemotherapy pharmacy compounding unit provided data on dose delays, dose reductions during treatment, and treatment discontinuation. Reasons for discontinuation and hospitalizations were collected from retrospective review of patient records. We opted to use these outcomes as opposed to the NCI-CTCAE Grade 3–5 toxicity to ensure accuracy of reporting, where all grade 3 toxicity not requiring hospitalization may not be captured retrospectively.

2.4. Data Analysis

The mean, standard deviation, and range for continuous variables and the frequencies for categorical variables were calculated as part of a descriptive analysis using Microsoft Excel. Tests for the statistical significance of single variables were performed using the Student’s t-test, while two-variable correlations were assessed pairwise using the Fisher’s Exact Test.

We examined six potential pre- and post-treatment interactions. These were predetermined prior to analysis. Using Fisher’s Exact Tests with either 2 × 2 or 3 × 2 contingency tables, we sought to examine whether either the CARG risk score for each patient at baseline/pre-modification of treatment (low, medium, or high) or the presence/absence of cognitive impairment could be related to one of three post-treatment outcomes: dose reduction due to toxicity, discontinuation due to toxicity, or hospitalization due to toxicity. A p value of 0.05 was considered significant.

3. Results

Data on 94 patients aged ≥70 who received cytotoxic therapy were analysed. Patient demographics are summarized in Table 1. About half were male, 76% (n = 71) had an ECOG PS of 1 and 77% (n = 72) had a diagnosis of gastrointestinal cancer. Thirty eight percent (n = 38) had metastatic disease and forty nine percent (n = 46) were treated with polychemotherapy.
Table 1. Patient Demographics.

| Variable (n = 94)          | n   | %   |
|---------------------------|-----|-----|
| Age (years)               |     |     |
| Mean                      | 76.49 | —   |
| Median (range)            | 76 (70–87) | —   |
| Gender                    |     |     |
| Male                      | 45  | 48  |
| Female                    | 49  | 52  |
| ECOG PS                   |     |     |
| 0                         | 4   | 4   |
| I                         | 71  | 76  |
| II                        | 16  | 17  |
| III                       | 2   | 2   |
| IV                        | 1   | 1   |
| Cancer Type               |     |     |
| Gastrointestinal          | 72  | 77  |
| Breast                    | 8   | 9   |
| Genitourinary             | 5   | 5   |
| Gynaecological            | 2   | 2   |
| Lung                      | 7   | 7   |
| Cancer Stage              |     |     |
| I                         | 1   | 1   |
| II                        | 11  | 12  |
| III                       | 44  | 47  |
| IV                        | 38  | 38  |
| Treatment Intent          |     |     |
| Curative                  | 48  | 51  |
| Palliative                | 46  | 49  |
| Treatment Regimen         |     |     |
| Monotherapy               | 48  | 51  |
| Polytherapy               | 46  | 49  |

Eastern Cooperative Oncology Group Performance Status.

3.1. Comprehensive Geriatric Assessment

We gathered data on 11 variables for the CGA (Table 2). The median TUG score was 11 s (range 2.79–31.6). Only 9 of the 94 study participants (9%) had a fall within the last 6 months. Twelve patients (13%) scored > 5 on the geriatric depression scale, and more than half of patients (62%) scored ≥ 3 on the Charlson Comorbidity Index. Nearly one-third of patients (29%) displayed cognitive impairment. Median BMI was 26.93 (15.43–39.25), with 70% at risk or frankly malnourished by the MNA. Using the CARG toxicity risk calculator, 47% (n = 44) were deemed at medium risk and 46% (n = 43) at high risk of toxicity.

3.2. Treatment Outcomes

The four toxicity-dependent outcomes are shown in Table 3. About one-third to one-half of all patients experienced toxicity severe enough to warrant some significant alteration in their treatment plans. A delay in the administration of subsequent doses was the most common outcome, with 55% (n = 52) of all patients requiring this modification. A total of 42% (n = 39) required a discontinuation of their treatment due to toxicity, and 36% (n = 34) required hospitalization with toxicity. Data on the prevalence of geriatric deficits in different subgroups of patients who experienced toxicities are shown in Supplementary Table S2.
3.3. Statistical Analysis of Toxicity Correlations

Six potential pre- and post-treatment interactions are outlined in Table 4. None of the associations exhibited a significant relationship.

Table 2. Geriatric Assessment Variables.

| Variable                        | n   | %   |
|---------------------------------|-----|-----|
| Timed Up and Go                 |     |     |
| Mean                            | 11.99 s | —  |
| Median (range)                  | 11 (7.79–31.6) s | —  |
| Falls in the last 6 months      |     |     |
| Yes                             | 8   | 9   |
| No                              | 85  | 90  |
| N/A                             | 1   | 1   |
| Concomitant meds                |     |     |
| Mean                            | 6.32 | —  |
| Median (range)                  | 6 (0–19) | —  |
| Mini Nutritional Assessment (MNA) |     |     |
| 0–7                             | 28  | 30  |
| 8–11                            | 51  | 54  |
| 12–14                           | 15  | 16  |
| Body mass index                 |     |     |
| Mean                            | 27.02 | —  |
| Median (range)                  | 26.93 (15.43–39.25) | —  |
| Geriatric depression scale      |     |     |
| ≤5                              | 79  | 84  |
| >5                              | 12  | 13  |
| N/A                             | 3   | 3   |
| Katz ADLs                       |     |     |
| Mean                            | 5.74 | —  |
| Median (range)                  | 6 (3–6) | —  |
| Lawton IADLs                    |     |     |
| Mean                            | 7.44 | —  |
| Median (range)                  | 8 (3–8) | —  |
| Charlson Comorbidity Index      |     |     |
| 0                               | 0   | 0   |
| 1–2                             | 32  | 34  |
| 3–4                             | 20  | 21  |
| ≥5                              | 42  | 45  |
| * Cognitive impairment          |     |     |
| Yes                             | 27  | 29  |
| No                              | 61  | 65  |
| N/A                             | 6   | 6   |
| CARG toxicity risk              |     |     |
| Low                             | 4   | 4   |
| Medium                          | 44  | 47  |
| High                            | 43  | 46  |
| N/A                             | 3   | 3   |

N/A = not available; Activities of Daily Living; Instrumental Activities of Daily Living; Cancer and Aging Research Group. * Cognitive impairment defined as MOCA < 26.
Table 3. Treatment Outcomes.

| Outcome                          | n   | %  |
|----------------------------------|-----|----|
| Baseline dose reduction          |     |    |
| Yes                              | 24  | 26 |
| No                               | 67  | 71 |
| N/A                              | 3   | 3  |
| Subsequent dose reduction        |     |    |
| Yes                              | 26  | 28 |
| No                               | 60  | 64 |
| N/A                              | 8   | 8  |
| Dose delay                       |     |    |
| Yes                              | 52  | 55 |
| No                               | 36  | 39 |
| N/A                              | 6   | 6  |
| Discontinuation due to toxicity  |     |    |
| Yes                              | 39  | 42 |
| No                               | 51  | 54 |
| N/A                              | 4   | 4  |
| Hospitalization due to toxicity  |     |    |
| Yes                              | 34  | 36 |
| No                               | 56  | 60 |
| N/A                              | 4   | 4  |

Table 4. Fisher’s Exact Tests for interdependence of pre- and post-treatment parameters.

| Post-Treatment Status | Pre-Treatment Status | p Value |
|-----------------------|----------------------|---------|
| Dose reduction (Y/N)  | CARG risk (Low/Med/High) | 0.712  |
| Toxicity (Y/N)        | CARG risk (Low/Med/High) | 0.367  |
| Hospitalization (Y/N) | CARG risk (Low/Med/High) | 0.509  |
| Dose reduction (Y/N)  | Cognitive impairment (Y/N) | 0.340  |
| Toxicity (Y/N)        | Cognitive impairment (Y/N) | 0.347  |
| Hospitalization (Y/N) | Cognitive impairment (Y/N) | 1.0    |

1 A 3 × 2 contingency table was used. 2 A 2 × 2 contingency table was used. Y = yes, N = No; CARG = Cancer and Aging Research Group.

4. Discussion

Our data show the vulnerability of older patients with cancer to the toxic effects of chemotherapy and thus the importance of a multidisciplinary and tailored approach to each patient. Innumerable drug studies report the comparable benefit of systemic anticancer therapy in older and younger adults [46,47]. However, these studies nearly universally report the higher risk of toxicity in the older cohort. Thus, optimizing treatment decisions and generating bespoke treatment plans, incorporating the cancer diagnosis and stage, as well as the physiological and pathological changes in the older adult is essential. While unplanned hospitalization and dose modifications is an accepted component of cancer care, the rates in our group remain substantial, though comparable to larger, randomized studies recently reported [31,32].

The GAIN study [31] enrolled 613 patients aged ≥65 with a solid malignancy who were due to start a new chemotherapy regimen and had completed a CGA. Patients were randomized (2:1) to either the intervention or standard care arm. The primary outcome was the incidence of grade 3 or higher chemotherapy-related toxic effects. Secondary outcomes included emergency department visits, unplanned hospitalizations, chemotherapy dose modification, and early discontinuation. In this study, 27% had an emergency department visit and 22% had an unplanned hospitalization in the intervention arm. Fifty-four percent discontinued chemotherapy early and fifty-four percent required chemotherapy dose mod-
fications (reductions and delays). In contrast to our service, a full geriatrics-trained multi-disciplinary team was involved in reviewing the baseline assessments, in recommending appropriate interventions, and initiating referrals in the GAIN study.

The GAP70+ study [32] was a cluster-randomized trial, enrolling patients \( \geq 70 \) years with incurable solid tumours or lymphoma. In this study, patients were required to have at least one impaired geriatric assessment domain. Patients were randomized to the intervention arm, where oncologists received a tailored geriatric assessment summary and management recommendations, or to the usual care arm, where no geriatric assessment or summary was provided to oncologists. We utilize a similar approach, however, in the GOAL clinic the referrals are initiated by the geriatric oncology ANP and are not solely at the discretion of the primary oncologist. The primary outcome in the GAP70+ study was the rate of grade 3–5 toxicities. In this study, a higher proportion of patients in the intervention arm received treatment at a reduced dose intensity than standard in cycle one (49%), and 43% required dose reductions because of toxic effects over three months in the intervention arm.

While both the GAP and GAIN studies have proven the benefit of geriatric assessment and intervention in reducing significant toxic effects from cancer treatment, the rates of hospitalization and treatment modifications remain high in both studies. Our data showed similar findings, despite the use of the CGA, pre-treatment modifications in 26% based on the CARG toxicity calculator, and targeted interventions of any deficits identified on the baseline assessment. However, the rates would be significantly higher outside the setting of a geriatric-focused clinical service. INTEGERATE was a prospective, randomized, parallel group study in patients aged \( >70 \) years with cancer planned for chemotherapy, targeted therapy, or immunotherapy [33]. Patients were randomly assigned to receive either geriatrician-led comprehensive geriatric assessment or management integrated with usual care (integrated oncogeriatric care) or usual care alone. While the primary outcome was health-related quality of life measured by the Elderly Functional Index (ELFI) score, a major secondary outcome included healthcare utilization. In this study, there were 39% less emergency presentations, 41% less unplanned hospital admissions, and 24% less unplanned hospital overnight bed days in the integrated oncogeriatric care arm.

Other studies have reported correlations between the CARG risk score and toxicities in geriatric oncology patients [48–50]. Within our data set, there was no clear CARG risk status or cognitive impairment status that would accurately predict the toxicity-driven negative outcome of a chemotherapy treatment. We modified our initial treatment decisions based on the baseline CARG risk. Thus we can infer benefit from this approach as those at high risk at baseline were at no greater risk than medium or low risk after treatment modification.

Our results came despite a seemingly healthy population at baseline. The median TUG score was 11 s; a score greater than 13.5 s is the convention to identify those at increased risk of falls in the community [37]. Only 9 of the 94 study participants (9%) had a fall within the last 6 months, while the literature reports that about 20–30% of elderly patients with cancer will fall within a year [51]. In addition, 80% had a performance status of 0 or 1. However, it is acknowledged that performance status is not a good marker in older adults [24,52]. On the other hand, the data identified vulnerabilities in terms of nutrition with high rates of malnutrition in at-risk groups and polypharmacy. Cognitive impairment was noted in 29% of patients, which is significantly higher than seen in the GAIN study (6.7%) and cognitive impairment reported in 40% of the GAP70+ study population. Two-thirds of patients had a significant co-morbidity burden, comparable to randomized studies. Consequently, the population was putatively at some risk for chemotherapy toxicity despite seemingly being healthy outside their oncological status.

The current study has some limitations, including its retrospective nature, relatively small sample size, no comparator population available, and we included predominantly a population with GI malignancies. Nonetheless, it is the only toxicity data from an Irish population of older patients seen in a dedicated geriatric-oncology service.
Our data confirm the significant risk of toxicity from cytotoxic therapy in an older population. Randomized data confirms the benefit of geriatric assessments and interventions to decrease toxicity risks. It is important to develop, support, and resource geriatric-oncology services to allow ongoing, multidisciplinary input throughout the course of treatment in an effort to proactively manage and modify treatments, decrease healthcare utilization, decrease treatment risks, and improve quality of life for our older patients with cancer.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/curroncol29090484/s1, Table S1: Geriatric Assessments and interventions; Table S2: Toxicity subgroups and CGA deficits.

**Author Contributions:** Conceptualization, A.M.H. and M.H. (Munzir Hamid); methodology, A.M.H. and M.H. (Munzir Hamid); software, A.M.H. and M.H. (Munzir Hamid); validation, A.M.H. and M.H. (Munzir Hamid); formal analysis, A.M.H., M.H. (Munzir Hamid) and S.M.; data curation, A.M.H., M.H. (Munzir Hamid), M.H. (Michelle Hannan), N.M.O., F.L., D.J.W., T.M., M.O. and P.C.; supervision, A.M.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of University Hospital Waterford, Ireland (protocol code: 130, date of approval: 11 October 2021).

**Informed Consent Statement:** Patient consent was waived. This was a low-risk, retrospective study where data had already been obtained by the controller for the purposes of the provision of health care to an individual. The REC was satisfied that the required data protection risk assessment carried out by the controller indicated a low risk to the rights and freedoms of the data subjects whose data was accessed and used in the study. Thus, as per the Health Research Regulations guidance on retrospective chart review (Ireland, January 2021), consent was not required.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author for scientific purposes.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Pilleron, S.; Sarfati, D.; Janssen-Heijnen, M.; Vignat, J.; Ferlay, J.; Bray, F.; Soerjomataram, I. Global cancer incidence in older adults, 2012 and 2035: A population-based study. *Int. J. Cancer* 2019, 144, 49–58. [CrossRef] [PubMed]
2. Gajra, A.; Klepin, H.D.; Feng, T.; Tew, W.P.; Mohile, S.G.; Owusu, C.; Cross, C.P.; Lichtman, S.M.; Wildes, T.M.; Chapman, A.E.; et al. Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors. *J. Geriatr. Oncol.* 2015, 6, 133–140. [CrossRef] [PubMed]
3. Retornaz, F.; Guillem, O.; Rousseau, F.; Morvan, F.; Rinaldi, Y.; Nahon, S.; Castagna, C.; Boulahssass, R.; Grino, M.; Gholam, D. Predicting chemotherapy toxicity and death in older adults with colon cancer: Results of MOST Study. *Oncologist* 2020, 25, e85–e93. [CrossRef]
4. Hurria, A.; Soto-Perez-de-Celis, E.; Blanchard, S.; Burhenn, P.; Yeon, C.H.; Yuan, Y.; Li, D.; Katheria, V.; Waisman, J.R.; Luu, T.H.; et al. A Phase II trial of older adults with metastatic breast cancer receiving Nab-Paclitaxel: Melding the fields of geriatrics and oncology. *Clin. Breast Cancer* 2019, 19, 89–96. [CrossRef] [PubMed]
5. Moth, E.B.; Kiely, B.E.; Stefanic, N.; Naganathan, V.; Martin, A.; Grimison, P.; Stockler, M.R.; Beale, P.; Blinman, P. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG toxicity score with oncologists’ estimates of toxicity based on clinical judgement. *J. Geriatr. Oncol.* 2019, 10, 202–209. [CrossRef]
6. Wang, S.; Wong, M.L.; Hamilton, N.; Davoren, J.B.; Jahan, T.M.; Walter, L.C. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. *J. Clin. Oncol.* 2012, 30, 1447–1455. [CrossRef]
7. Pal, S.K.; Hurria, A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. *J. Clin. Oncol.* 2010, 28, 4086–4093. [CrossRef]
8. Yan, H.; Winchester, D.J.; Prinz, R.A.; Wang, C.-H.; Nakazato, Y.; Moo-Young, T.A. Differences in the impact of age on mortality in well-differentiated thyroid cancer. *Ann. Surg. Oncol.* 2018, 25, 3193–3199. [CrossRef]
9. Nogami, N.; Nishio, M.; Okamoto, I.; Enatsu, S.; Suzukawa, K.; Takai, H.; Nakagawa, K.; Tamura, T. Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. *Respir. Investig.* 2019, 57, 27–33. [CrossRef]
10. Winther, S.B.; Liposits, G.; Skuladottir, H.; Hofsl, E.; Shah, C.-H.; Poulsen, L.O.; Ryg, J.; Osterlund, P.; Berglund, Å.; Qvortrup, C.; et al. Reduced-dose combination chemotherapy (S-1 plus Oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable
33. Soo, W.-K.; King, M.; Pope, A.; Parente, P.; Darzins, P.; Davis, I. Integrated geriatric assessment and treatment (INTEGRATE) in older people with cancer planned for systemic anticancer therapy. J. Clin. Oncol. 2020, 38, 12011. [CrossRef]
34. Bellera, C.A.; Rainfray, M.; Mathoulin-Pelissier, S.; Mertens, C.; Delva, F.; Fonck, M.; Soubeyran, P.L. Screening older cancer patients: First evaluation of the G-8 geriatric screening tool. Ann. Oncol. 2012, 23, 2166–2172. [CrossRef]
35. Extermann, M.; Boler, I.; Reich, R.R.; Lyman, G.H.; Brown, R.H.; DeFelice, J.; Levine, R.M.; Lubiner, E.T.; Reyes, P.; Schreiber, F.J.; et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012, 118, 3377–3386. [CrossRef]
36. Horta, A.; Togawa, K.; Mohile, S.G.; Owusu, C.; Klepin, H.D.; Gross, C.P.; Lichtman, S.M.; Gajra, A.; Bhatia, S.; Katheria, V.; et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J. Clin. Oncol. 2011, 29, 3457–3465. [CrossRef]
37. Barry, E.; Galvin, R.; Keogh, C.; Horgan, F.; Fahey, T. Is the Timed Up and Go test a useful predictor of risk of falls in community dwelling older adults: A systematic review and meta-analysis. BMC Geriatr. 2014, 14, 14. [CrossRef]
38. Vellas, B.; Guigoz, Y.; Garry, P.; Bennahum, D.; Lauque, S.; Albarede, J.L. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999, 15, 116–122. [CrossRef]
39. Cereda, E. Mini Nutritional Assessment. Curr. Opin. Clin. Nutr. Metab. Care 2016, 12, 29–41. [CrossRef]
40. Yesavage, J.A.; Sheikh, J.I. 9/Geriatric depression scale (GDS) recent evidence and development of a shorter version. Clin. Gerontol. 1986, 5, 165–173. [CrossRef]
41. de Ferretti-Rebustini, R.E.L.; Balbinotti, M.A.A.; Jacob-Filho, W.; Reustl, C.K.; Pasquale, C.A.G.; Farfel, J.M.; Leite, R.E.P.; Grinberg, L.T.; Nitrini, R. Validity of the Katz Index to assess activities of daily living by informants in neuropathological studies. Rev. Esc. Enferm. USP 2015, 49, 946–952. [CrossRef] [PubMed]
42. Langer, C.J.; Manola, J.; Bernardo, P.; Kugler, J.W.; Bonomi, P.; Cella, D.; Johnson, D.H. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl. Cancer Inst. 2002, 94, 173–181. [CrossRef] [PubMed]
43. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic. Dis. 1987, 40, 373–383. [CrossRef]
44. Brooke, P.; Bullock, R. Validation of a 6 Item Cognitive Impairment Test with a view to primary care usage. Int. J. Geriatr. Psychiatry 1999, 14, 936–940. [CrossRef]
45. Nasreddine, Z.S.; Phillips, N.A.; Bédirian, V.; Charbonneau, S.; Whitehead, V.; Collin, I.; Cummings, J.L.; Chertkow, H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005, 53, 695–699. [CrossRef]
46. Arciero, V.S.; Cheng, S.; Mason, R.; McDonald, E.; Saluja, R.; Chan, K.K.W. Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis. Age Ageing 2018, 47, 654–660. [CrossRef]
47. Elias, R.; Giobbie-Hurder, A.; Cleary, N.J.; Ott, P.; Hodi, F.S.; Rahma, O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: A meta-analysis. J. Immunother. Cancer 2018, 6, 26. [CrossRef]
48. Nie, X.; Liu, D.; Li, Q.; Bai, C. Predicting chemotherapy toxicity in older patients with lung cancer. J. Geriatr. Oncol. 2013, 4, 334–339. [CrossRef]
49. Alibhai, S.M.H.; Aziz, S.; Manokumar, T.; Timilshina, N.; Breunis, H. A comparison of the CARG tool, the VES-13, and oncologist recommendations for chemotherapy for stage IV lung cancer: What is the role of performance status? J. Clin. Oncol. Pract. 2015, 6, 70–83. [CrossRef] [PubMed]
50. Tisnado, D.; Malin, J.; Kahn, K.; Landrum, M.B.; Fletcher, R.; Klabunde, C.; Clauser, S.; Rogers, S.O.; Jr.; Keating, N.L. Variations in oncologist recommendations for chemotherapy for stage IV lung cancer: What is the role of performance status? J. Oncol. Pract. 2016, 12, 653–662. [CrossRef] [PubMed]